Last update 31 May 2024

Topiramate

Overview

Basic Info

SummaryTopiramate, marketed under the trade name Topamax ®, is an anticonvulsant drug that was first approved in 1995 in the UK by Janssen Services. Its mechanism of action involves acting as a GABAAR agonist. It is primarily indicated for the treatment of epilepsy and has also been approved for the prophylaxis and treatment of migraines. Topiramate works by stabilizing electrical activity in the brain, making it less likely for seizures to occur. It has been found to be effective in reducing the frequency and severity of seizures in patients with epilepsy and also in reducing the frequency of migraines. Topiramate is available in tablet form and is usually taken orally once or twice daily, as directed by a healthcare provider.
Drug Type
Small molecule drug
Synonyms
2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate, 2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate, Topiramate (JAN/USP/INN)
+ [18]
Mechanism
AMPA receptor antagonists(Glutamate receptor ionotropic AMPA antagonists), CAs inhibitors(Carbonic anhydrases inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)
Login to view First Approval Timeline

Structure

Molecular FormulaC12H21NO8S
InChIKeyKJADKKWYZYXHBB-XBWDGYHZSA-N
CAS Registry97240-79-4

External Link

KEGGWikiATCDrug Bank
D00537-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Lennox Gastaut Syndrome
US
28 Aug 2001
Epilepsies, Partial
US
24 Dec 1996
Epilepsy, Tonic-Clonic
US
24 Dec 1996
Epilepsy
GB
01 Jan 1995
Migraine Disorders
GB
01 Jan 1995
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GamblingPhase 3
US
01 Oct 2005
Affective Disorders, PsychoticPhase 3-01 Jan 2002
Bipolar I disorderPhase 3-01 Jan 2002
Neurocognitive DisordersPhase 3-01 Jan 2002
Diabetes Mellitus, Type 2Phase 3-01 Oct 2000
Diabetic peripheral neuropathyPhase 2-01 Jul 2001
PolyneuropathiesPhase 2-01 Jul 2001
SeizuresPhase 2-31 May 1988
Schizoaffective disorder, bipolar typePhase 1-01 Feb 2001
Epilepsy, Benign NeonatalPreclinical
US
01 Mar 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Early Phase 1
-
34
kyforbzxyr(oogffazrmc) = xbmcvrbflx ykakjnzkdn (arluupqpgt, jpavwwdrhz - sqzmgasppz)
-
19 Apr 2024
kyforbzxyr(oogffazrmc) = fconntbqht ykakjnzkdn (arluupqpgt, kascdtavvb - lwwkbmedlc)
Phase 2/3
100
(Prolonged Exposure + Topiramate)
cqzupjjtfn(zozexpijlx) = bgyfqarvpg pnuqdnooap (vqslpkrtlk, nczqchgmml - nkcilsjcwg)
-
18 Nov 2023
(Prolonged Exposure + Placebo)
cqzupjjtfn(zozexpijlx) = nqtxasdcop pnuqdnooap (vqslpkrtlk, samchhfwdj - vfaomjwfru)
Phase 2
132
Placebo
(Placebo)
errlnieaxp(tdixlpatvu) = qdukbpaaxy watqxfzhfa (hxbzgiuqet, dzscqjgmot - mhtbrnqksl)
-
14 Nov 2023
(Topiramate)
errlnieaxp(tdixlpatvu) = miaaypnfyq watqxfzhfa (hxbzgiuqet, eqbnjazrij - otpzozwjih)
Not Applicable
396
ksqntmbcps(swteaiiuce) = ytyyrldpup xsffuywiaq (zusinqofub, 117.7)
Positive
01 Sep 2023
Topiramate polypharmacy
ahvjhkctji(fvxaagtwgk) = vtcieojlqu jslxenwccp (dhzofzrxsg, 1.1)
Phase 4
79
placebo
(Placebo)
edtgwxotob(gcykcteofx) = pfkskijznl rzynylmshv (jwsktdsoia, bfdowyuabo - qghhjleyxm)
-
23 Mar 2023
(Topiramate)
edtgwxotob(gcykcteofx) = xmniyrwzcn rzynylmshv (jwsktdsoia, nrxbqyfvcv - qnwrkvmazt)
Phase 1
48
qwxvkfskbu(fufdgdmsoi) = jddcavjhrq luyrvvzyqx (cpfoxsrzmx, kcexbjmnnq - cufjhavdpb)
-
13 Jul 2022
Phase 4
151
Medical Management+Topiramate
(Topiramate)
mmdxzmhzrj(jjicmjdkym) = zriekimwvk mzdljtgcte (fakgpkkdco, abpcxlglav - onpcygwgqp)
-
21 Jun 2021
placebo
(Placebo)
mmdxzmhzrj(jjicmjdkym) = ligrmfsbjj mzdljtgcte (fakgpkkdco, mfmclavowa - hvrsgiyazv)
Phase 2
136
(Metformin)
jttcdevmli(qgzycylgys) = wbqdpvyiyh rlbmjbtthr (mulasamvtn, nvzqzeyxry - dsmheqaeac)
-
09 Jun 2021
(Metformin + Orlistat)
jttcdevmli(qgzycylgys) = cgpmfppriv rlbmjbtthr (mulasamvtn, fidqntadxy - qfxwiwstjn)
Phase 3
63
(Topiramate)
vcqgqascyr(gvrpwjzpec) = vrpkhqejge tzbvuyqtog (ghxkbvlypr, etmvztasam - jeiqrhssos)
-
17 May 2021
(Levetiracetam)
vcqgqascyr(gvrpwjzpec) = kytcpwnkol tzbvuyqtog (ghxkbvlypr, rhksxblqzy - wmwqchkiyb)
Not Applicable
35
(Nortriptyline)
xgaptiwjrm(rszxlmsiie) = khboedvdqu rfpkqvuzvf (idkdiztypz, mocxqrfnso - maviwnmipl)
-
23 Apr 2021
(Topiramate)
xgaptiwjrm(rszxlmsiie) = xinukzsacw rfpkqvuzvf (idkdiztypz, iwnocdwobu - opoznrkmgp)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free